Advertisement

An executive at Aveo Oncology (Nasdaq: AVEO) on Tuesday told Mass High Tech that plans to cut 75 positions - more than half through layoffs - have no bearing on the expected launch of the company’s first drug, now pending approval.

Advertisement
Advertisement